Free Trial

Jyong Biotech Ltd.'s Quiet Period Set To Expire on July 28th (NASDAQ:MENS)

Jyong Biotech's (NASDAQ:MENS - Get Free Report) quiet period will expire on Monday, July 28th. Jyong Biotech had issued 2,666,667 shares in its public offering on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. During the company's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.

View Our Latest Research Report on Jyong Biotech

Jyong Biotech Stock Down 4.2%

NASDAQ:MENS opened at $10.55 on Monday. Jyong Biotech has a 52 week low of $6.01 and a 52 week high of $19.99.

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jyong Biotech Right Now?

Before you consider Jyong Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.

While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines